Skip to Content
Merck
CN

Key Documents

View All Documentation

EHU056301

MISSION® esiRNA

targeting human DTX3L

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

GCAGACAGTAAGCAGGCAAATAAATTCAAACAGGAATTGAATCACCAGTTTACAAAGCTCCTTATAAAGGAGAAAGGAGGCGAATTAACTCTCCTTGGGACCCAAGATGACATTTCAGCTGCCAAACAAAAAATCTCTGAAGCTTTTGTCAAGATACCTGTGAAACTATTTGCTGCCAATTACATGATGAATGTAATTGAGGTTGATAGTGCCCACTATAAACTTTTAGAAACTGAATTACTACAGGAGATATCAGAGATCGAAAAAAGGTATGACATTTGCAGCAAGGTTTCTGAGAAAGGTCAGAAAACCTGCATTCTGTTTGAATCCAAGGACAGGCAGGTAGATCTATCTGTGCATGCTTATGCAAGTTTCATCGATGCCTTTCAACATGCCTCATGTCAGTTGATGAGAGAAGTTCTTTTACTGAAGTCTTTGGGCAAGGAG

Ensembl | human accession no.

ENSG00000163840

NCBI accession no.

NM_138287

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... DTX3L(151636)

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
ZYU
KXU
QCS

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Danielle P Johnson et al.
Oncotarget, 6(7), 4863-4887 (2015-01-22)
Gain-of-function mutations in the catalytic site of EZH2 (Enhancer of Zeste Homologue 2), is observed in about 22% of diffuse large B-cell lymphoma (DLBCL) cases. Here we show that selective inhibition of histone deacetylase 1,2 (HDAC1,2) activity using a small

Global Trade Item Number

SKUGTIN
EHU056301-20UG04061828559350
EHU056301-50UG04061828325115